Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC)
Autor: | Michael Thomas, Juergen R. Fischer, Philipp A. Schnabel, Christian Grah, Stefan Andreas, Dirk Behringer, Niels Reinmuth, R. Heine, Alexander Reuss, Monika Serke, Christian Witt, Cornelius Kortsik, M. Schroeder, Jens Kollmeier, Ernst Müller, M. Schenk, Martin Wolf, Thomas Acker, L. J. Müller, M. von Eiff |
---|---|
Rok vydání: | 2011 |
Předmět: | |
Zdroj: | Journal of Clinical Oncology. 29:7504-7504 |
ISSN: | 1527-7755 0732-183X |
Popis: | 7504 Background: Combining EGFR kinase inhibition (E) with an anti-VEGF strategy (B) showed promising activity (RR 20%; PFS 6.2 months) in recurrent NS-NSCLC (J Clin Oncol (2005) 23: 2544). To asse... |
Databáze: | OpenAIRE |
Externí odkaz: |